A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Liverpool
• Collaborators: Chugai Pharma USA; GlaxoSmithKline; Napp Pharmaceuticals Limited
• Treatments: Antibodies, Monoclonal; Bendamustine Hydrochloride; Chlorambucil; Ofatumumab

Criteria

Inclusion Criteria:

1. CLL/SLL requiring treatment by NCI/IWCLL 2008 criteria. At least one of the following criteria:

1. Progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia.

2. Massive (i.e. 6 cm below the left costal margin) or progressive or symptomatic splenomegaly.

3. Massive (i.e. 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.

4. Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months.

2. No prior cytotoxic or targeted therapy for CLL

3. Full-dose R-FC considered inappropriate for at least one of the following reasons

1. Age 75 or greater

2. WHO performance status 2 or 3

3. Cardiac impairment (NYHA class II)

4. Respiratory impairment (bronchiectasis or moderate COPD)

5. Renal impairment (estimated Glomerular Filtration Rate (eGFR) 10-30 ml/min)

6. Any other significant co-morbidity or factor that makes R-FC inappropriate

4. Considered able to tolerate Chl at the dose used in the LRF CLL4 trial (10mg/m2 d1-7)

5. Written informed consent

Exclusion Criteria:

1. Neutrophil count less than 1.0 x 109/l or platelet count less than 50 x 109/l unless due to CLL

2. Uncontrolled auto-immune haemolytic anaemia or thrombocytopenia

3. Active infection

4. Seropositivity for HIV, HCV or HBV (surface antigen or and core antibody)

5. Severe renal impairment (eGFR less than 10ml/min)

6. Severe hepatic impairment (serum bilirubin more than twice the upper limit of normal) unless due to CLL or Gilbert's syndrome.

7. Concurrent treatment with glucocorticoids equivalent to more than prednisolone 20mg od

8. Prior treatment with monoclonal antibody therapy within the last 3 months.

9. Yellow fever vaccination within 4 weeks prior to treatment start

10. Known hypersensitivity to ofatumumab, bendamustine or chlorambucil or any of their excipients

11. CNS involvement with CLL

12. History of Richter transformation

13. Concomitant malignancies within the last 3 years except successfully treated non-melanoma skin cancer or carcinoma in situ.

14. Major surgery within 28 days prior to randomisation

15. WHO performance status 4

16. Severe cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (NYHA III-IV), and arrhythmia (excluding extra systoles or minor conduction abnormalities) unless controlled by therapy.

17. Any serious underlying medical or psychological conditions, which could impair the ability of the patient to participate in the trial or compromise ability to give informed consent

18. Treatment within a clinical trial within 30 days prior to trial entry.

19. Adult patient under tutelage (not competent to sign informed consent).

20. Pregnant or lactating women.

21. Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.

22. Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.